Treatment with CDK7/9 inhibitors together with venetoclax resulted in increased DLBCL, follicular lymphoma, and marginal zone lymphoma patient sample cell death (Figure 5D). The gene discussed is CDK7; the disease is diffuse large B-cell lymphoma.